CORDIS
Forschungsergebnisse der EU

CORDIS

Deutsch DE
Deciphering the Metabolism of Haematological Cancers

Deciphering the Metabolism of Haematological Cancers

Ziel

It has long been realised that metabolism is central to cellular development, proliferation and homeostasis. Collectively, aberrations in metabolism are now recognised as a major hallmark of cancer, opening new avenues for personalised medicine. As haematological malignancies are multi-factorial diseases, our main emphasis will be on the integration of biomedical multi-omics data and computational systems modelling with the ultimate aim to understand metabolic regulation in haematological cancers. HaemMetabolism is design to unravel the regulatory mechanisms that link cell cycle control and metabolism. For this we will screen a panel of haematological cancer cell lines for the metabolic phenotypes and against a library of inhibitors. Gene-function analyses will be performed using shRNA libraries directed against key metabolome regulators. Validation will occur in primary patient samples in vitro and in vivo in preclinical humanized niche xenograft mouse models. A systems biomedicine approach will be integrated build genome-scale transcriptional models that explain deregulated metabolic pathways relevant for the development of haematological malignancies. This work will not only open new avenues for drug discovery but will also provide a multi-disciplinary framework for student training in biomedical technologies.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Koordinator

THE UNIVERSITY OF BIRMINGHAM

Adresse

Edgbaston
B15 2tt Birmingham

Vereinigtes Königreich

Aktivitätstyp

Higher or Secondary Education Establishments

EU-Beitrag

€ 819 863,64

Beteiligte (3)

Alphabetisch sortieren

Nach EU-Beitrag sortieren

Alles aufklappen

ACADEMISCH ZIEKENHUIS GRONINGEN

Niederlande

EU-Beitrag

€ 510 748,56

UNIVERSITAT DE BARCELONA

Spanien

EU-Beitrag

€ 743 618,88

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Deutschland

EU-Beitrag

€ 498 432,96

Partner (3)

Alphabetisch sortieren

Alles aufklappen

Bruker

TavarGenix

LifeGlimmer

Projektinformationen

ID Finanzhilfevereinbarung: 675790

Status

Laufendes Projekt

  • Startdatum

    1 Oktober 2015

  • Enddatum

    30 September 2019

Finanziert unter:

H2020-EU.1.3.1.

  • Gesamtbudget:

    € 2 572 664,04

  • EU-Beitrag

    € 2 572 664,04

Koordiniert durch:

THE UNIVERSITY OF BIRMINGHAM

Vereinigtes Königreich